Title
Search
All Issues
4
Year: 2004  Vol. 8   Num. 1  - Jan/Mar Print:
Original Article
Texto Text in Portuguese
New Insights in the Treatment of Nasal Allergy
Nuovi Orientamenti Nell Trattamento della Rinite Allergica
Author(s):
Pasquale Cassano, Matteo Gelardi, Maria Luisa Fiorella, Michele Cassano.
Key words:
allergic rhinitis, cytological test.
Abstract:

Introduction: Allergic rhinitis represents a serious and long-lasting disease with many important symptoms that interfere with quality of life, compromise work efficiency and lay a heavy burden on health care costs. Treatment of allergic rhinitis can be performed with a large number of drugs that can control the illness when planned, guided and controlled. However, the treatment is often directed exclusively to the symptoms and is managed autonomously by the patients. Objective: To draw a new therapeutic strategy on the basis of a nasal cytology test, the gold standard in rhinopathy diagnosis. This test is able to control allergic rhinitis at every stage, especially when inflammation persists in asymptomatic form (minimal persistent inflammation). This is possible because a cytology test is able to reveal cells such as eosinophils, mast-cells and neutrophils. Methods: We compared the results of allergic rhinitis treatment in the same group of patients in two years. Therapy was guided in the first year by the anamnesis and clinical feature; in the second year, by a cytological test performed both in acute and in asymptomatic stage. Results: On the whole rhinocytogram-guided therapy appeared the best in every pollen allergy, leading to a better course of clinical picture and to a decrease in treatment duration with consequent improvement in the quality of life and reduction of health care costs. Conclusions: Prophylatic treatment based on a simple and cheap test as the nasal cytological test, is a good way of checking symptoms and avoiding chronic evolution and complications.

  Print:

 

All right reserved. Prohibited the reproduction of papers
without previous authorization of FORL © 1997- 2019